| Compound Information | SONAR Target prediction |
| Name: | DIGOXIN |
| Unique Identifier: | SPE01500247 |
| MolClass: | Checkout models in ver1.5 and ver1.0 |
| Molecular Formula: | |
| Molecular Weight: | 717.438 g/mol |
| X log p: | 0.108000000000001 (online calculus) |
| Lipinksi Failures | 1 |
| TPSA | 81.68 |
| Hydrogen Bond Donor Count: | 0 |
| Hydrogen Bond Acceptors Count: | 14 |
| Rotatable Bond Count: | 7 |
| Canonical Smiles: | CC1OC(CC(O)C1O)OC1C(O)CC(OC1C)OC1C(O)CC(OC1C)OC1CCC2(C)C(CCC3C2CC(O)C2 (C)C(CCC32O)C2COC(=O)C=2)C1 |
| Class: | sterol glycoside |
| Source: | Digitalis lanata or D. orientalis Lam., Scrophulariaceae |
| Reference: | J.Chem.Soc.1930: 508; 1954: 2012 |
| Therapeutics: | cardiac stimulant |
| Generic_name: | Digoxin |
| Chemical_iupac_name: | 4-[3-[5-[5-(4,5-dihydroxy-6-methyl-tetrahydropyran-2-yl)oxy-4-hydroxy-6-methyl-tetra hydropyran-2-yl]oxy-4-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-12,14-dihydroxy-10,1 3-dimethyl-2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17-hexadecahydro-1H-cyclopenta[a]phe nanthren-17-yl]-5H-furan-2-one |
| Drug_type: | Approved Drug |
| Pharmgkb_id: | PA449319 |
| Kegg_compound_id: | C06956 |
| Drugbank_id: | APRD00098 |
| Melting_point: | 248 - 250 oC |
| H2o_solubility: | Insoluble |
| Logp: | 1.969 |
| Cas_registry_number: | 20830-75-5 |
| Drug_category: | Cardiotonic Agents; Antiarrhythmic Agents; ATC:C01AA02; ATC:C01AA05; ATC:C01AA08 |
| Indication: | For the treatment and management of Congestive cardiac insufficiency, arrhythmias and heart failure. |
| Pharmacology: | Digoxin, a cardiac glycoside similar to digitoxin, is used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation. |
| Mechanism_of_action: | Digoxin inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Digoxin also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential. |
| Organisms_affected: | Humans and other mammals |
| Found: 205 nonactive as graph: single | with analogs | 1 2 3 4 5 6 7 8 9 10 Next >> [205] |
| Species: | 4932 |
| Condition: | BCK1 |
| Replicates: | 2 |
| Raw OD Value: r im | 0.9640±0.00714178 |
| Normalized OD Score: sc h | 1.0205±0.0139082 |
| Z-Score: | 0.4550±0.279838 |
| p-Value: | 0.655442 |
| Z-Factor: | -3.29353 |
| Fitness Defect: | 0.4224 |
| Bioactivity Statement: | Nonactive |
| ps |
| DBLink | Rows returned: 19 | 1 2 3 4 Next >> |
| 3061 | 4-[3-[5-[5-(4,5-dihydroxy-6-methyl-oxan-2-yl)oxy-4-hydroxy-6-methyl-oxan-2-yl]oxy-4-hydroxy-6-methyl-oxa n-2-yl]oxy-14-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenant hren-17-yl]-5H-furan-2-one |
| 3062 | 4-[3-[5-[5-(4,5-dihydroxy-6-methyl-oxan-2-yl)oxy-4-hydroxy-6-methyl-oxan-2-yl]oxy-4-hydroxy-6-methyl-oxa n-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]ph enanthren-17-yl]-5H-furan-2-one |
| 4166 | 4-[12,14-dihydroxy-3-[4-hydroxy-5-[4-hydroxy-5-(4-hydroxy-5-methoxy-6-methyl-oxan-2-yl)oxy-6-methyl-oxan -2-yl]oxy-6-methyl-oxan-2-yl]oxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopent a[a]phenanthren-17-yl]-5H-furan-2-one |
| 6281 | 4-[(3S,5R,8R,9S,10S,13R,14S,17R)-3-[(2S,4S,5R,6R)-5-[(2S,4S,5R,6R)-5-[(2S,4S,5R,6R)-4,5-dihydroxy-6-meth yl-oxan-2-yl]oxy-4-hydroxy-6-methyl-oxan-2-yl]oxy-4-hydroxy-6-methyl-oxan-2-yl]oxy-14-hydroxy-10,13-dime thyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-5H-furan-2-one |
| 27886 | 4-[(3S,5R,10S,13R,14S,17S)-3-[(2S,4S,5R,6R)-5-[(2S,4S,5R,6R)-4,5-dihydroxy-6-methyl-oxan-2-yl]oxy-4-hydr oxy-6-methyl-oxan-2-yl]oxy-14-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocycl openta[a]phenanthren-17-yl]-5H-furan-2-one |
| 30322 | 4-[(3S,5R,8R,9S,10S,12R,13S,14S)-3-[(2S,4S,5R,6R)-5-[(2S,4S,5R,6R)-5-[(2S,4S,5R,6R)-4,5-dihydroxy-6-meth yl-oxan-2-yl]oxy-4-hydroxy-6-methyl-oxan-2-yl]oxy-4-hydroxy-6-methyl-oxan-2-yl]oxy-12,14-dihydroxy-10,13 -dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-5H-furan-2-one |
| internal high similarity DBLink | Rows returned: 7 | 1 2 Next >> |
| SPE01501205 | 0.9327 |
| SPE01500986 | 0.9417 |
| SPE01501136 | 0.9495 |
| LOPAC 01110 | 0.9592 |
| SPE00100588 | 0.9592 |
| SPE01500676 | 0.9592 |
| active | Cluster 1442 | Additional Members: 8 | Rows returned: 0 |
Service provided by the
Mike Tyers Laboratory